HealthJ&J's Caplyta meets main goal of bipolar mania study

Johnson & Johnson said its experimental use of Caplyta for bipolar mania achieved the primary objective of a late-stage study, moving the drug closer to potential expansion beyond its current approved uses.

Johnson & JohnsonCaplytabipolar maniadrug trial

RReuters★★☆☆☆2026-09-21 14:10Original